文献速递免疫规划传染病防控与疫情报告

HIV垂直感染青少年接种Tdap加强针的免疫应答

Immune response to a Tdap booster in vertically HIV-infected adolescents.
PubMed 文献 · Vaccine · 2018-08-04

研究纳入30例CD4>200的HIV感染青少年和30例健康对照,均接种Tdap加强针。两组耐受良好并产生免疫应答,但HIV组百日咳血清转化率更低(62.1% vs 100%,p=.002),白喉抗体更低,细胞免疫应答较弱。病毒抑制的HIV感染者应答增强但仍低于对照。作者认为HIV感染青少年可能受益于更频繁的加强接种。

要点

  • HIV组百日咳血清转化率62.1% vs 对照组100%(p=.002)。
  • HIV组白喉抗体GMC 2.3(95%CI 0.88-6.19)低于对照16.4(95%CI 10.3-26.2)。
  • 病毒抑制的HIV青少年应答增强但仍低于对照组。

核心结论

  • 两组均耐受良好并产生免疫应答,但HIV感染青少年对百日咳的体液和细胞应答较弱,作者认为可能受益于更频繁的加强剂量。

研究设计与样本

  • 30例CD4细胞计数>200的HIV感染青少年和30例健康对照,此前均接受过全细胞DTP基础免疫,接种Tdap后采集血样。

主要发现

  • HIV组与对照组平均年龄分别为17.9岁和17.1岁,对照组注射部位疼痛更剧烈。
  • HIV组破伤风抗体28天GMC 15.6(95%CI 7.52-32.4),对照组GMC 23.1(95%CI 15.0-35.5)。
  • HIV组白喉抗体28天GMC 2.3(95%CI 0.88-6.19),低于对照组GMC 16.4(95%CI 10.3-26.2)。
  • 百日咳血清转化率HIV组62.1% vs 对照组100%(p=.002)。
  • 两组均产生针对破伤风的细胞免疫应答(Th2:IL-4、IL-5、IL-13;Th1:IFN-γ),HIV组细胞因子水平较低;针对百日咳,HIV组Th1和Th17应答较低、IL-10较高。

临床怎么用

  • 作者认为HIV感染青少年可能受益于更频繁的Tdap加强剂量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pertussis cases have increased worldwide and knowledge on immune response and cytokine profile after Tdap vaccine in immunodeficient adolescents is scarce. OBJECTIVE: To evaluate the immune response after Tdap in HIV-infected (HIV) and in healthy adolescents (CONTROL). METHODOLOGY: Thirty HIV adolescents with CD4 cell counts >200 and 30 CONTROLs were immunized with Tdap, after a prior whole-cell DTP vaccine primary scheme. Blood samples were collected immediately before and after vaccine. Lymphocyte immunophenotyping was performed by flow cytometry; tetanus, diphtheria and pertussis toxin antibodies were assessed by ELISA; whole blood was stimulated with tetanus toxoid and Bordetella pertussis and supernatants were assessed for cytokines by xMAP. RESULTS: Mean age of HIV and CONTROL groups were 17.9 e 17.1 years, respectively. Pain at injection site was more intense in CONTROL group. HIV group had similar increase in tetanus antibodies at 28 days (geometric mean concentration, GMC, 15.6; 95% CI, 7.52-32.4) than CONTROL group (GMC, 23.1; 95% CI, 15.0-35.5), but lower diphtheria antibodies at 28 days (GMC, 2.3; 95% CI, 0.88-6.19) than CONTROL group (GMC, 16.4; 95% CI, 10.3-26.2); for pertussis, the percentage of individuals who seroconverted was lower in HIV than CONTROL group (HIV, 62.1% versus CONTROL, 100%; p = .002). Both groups built a cellular immune response to tetanus, with a Th2 (IL-4, IL-5 and IL-13) and Th1 (IFN-γ) response, with lower cytokine levels in HIV than in CONTROL group. Especially for pertussis, cellular and humoral responses were less intense in HIV adolescents, with a lower Th1 and Th17 profile and higher IL-10 levels. HIV-infected adolescents on viral suppression showed an enhanced immune response to all the three vaccine antigens, although still at lower levels if compared to CONTROL group. CONCLUSIONS: Both groups tolerated well and built an immune response after Tdap. However, HIV-infected adolescents would probably benefit from more frequent booster doses.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Spina FG, Gouvea A, Succi RCM, et al. Immune response to a Tdap booster in vertically HIV-infected adolescents. Vaccine. 2018. PMID: 30087050. doi:10.1016/j.vaccine.2018.07.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。